Amphotericin B lipid preparations: What are the differences?

Clinical Microbiology and Infection

Volumn 14, Issue SUPPL. 4, 2008, Pages 25-36

  Adler moore, J P ^a   Proffitt, R T ^b  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^b RichPro Associates   (United States)

Author keywords

Amphotericin B; Combination antifungal therapy; Drug delivery; Drug toxicity; Preclinical studies; Review; Tissue localisation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; PLACEBO; PYRROLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; BLASTOMYCOSIS; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; LD 50; LUNG ASPERGILLOSIS; MONOTHERAPY; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SYSTEMIC MYCOSIS; TISSUE DISTRIBUTION; TOXICITY TESTING;

EID: 42649136929     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.01979.x     Document Type: Review

References (95)

1. D Ellis Amphotericin B: spectrum and resistance J Antimicrob Chemother 49 suppl 1 2002 7 10
2. NA Kshirsagar SK Pandya GB Kirodian S Sanath Liposomal drug delivery system from laboratory to clinic J Postgrad Med 51 suppl 1 2005 S5 S15
3. MA Hossain S Maesaki H Kakeya Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans Antimicrob Agents Chemother 42 1998 1722 1725
4. JA Olson JP Adler-Moore GM Jensen J Schwartz MC Dignani RT Proffitt Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products Antimicrob Agents Chemother 52 2008 259 268
5. JP Adler-Moore RT Proffitt Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B J Liposome Res 3 1993 429 450
6. G Fujii J-E Chang T Coley B Steere The formation of amphotericin B ion channels in lipid bilayers Biochemistry 36 1997 4959 4968
7. AS Janoff LT Boni MC Popescu Unusual lipid structures selectively reduce the toxicity of amphotericin B Proc Natl Acad Sci USA 85 1988 6122 6126
8. LSS Guo RM Fielding DD Lasic RL Hamilton D Mufson Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs Int J Pharma 75 1991 45 54
9. JW Lee MA Amantea PA Francis Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits Antimicrob Agents Chemother 38 1994 713 718
10. RM Fielding PC Smith LH Wang J Porter LS Guo Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats Antimicrob Agents Chemother 35 1991 1208 1213
11. M Ramaswamy KD Peteherych AL Kennedy KM Wasan Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities Antimicrob Agents Chemother 45 2001 1184 1191
12. SJ Olsen MR Swerdel B Blue JM Clark DP Bonner Tissue distribution of amphotericin B lipid complex in laboratory animals J Pharm Pharmacol 43 1991 831 835
13. GW Boswell D Buell I Bekersky AmBisome (liposomal amphotericin B): a comparative review J Clin Pharmacol 38 1998 583 592
14. AS Janoff WR Perkins SL Saletan CE Swenson Amphotericin B lipid complex(ABLC™): a molecular rationale for the attenuation of amphotericin B related toxicities J Liposome Res 3 1993 451 471
15. J Brajtburg G Medoff GS Kobayashi S Elberg C Finegold Permeabilizing and hemolytic action of large and small polyene antibiotics on human erythrocytes Antimicrob Agents Chemother 18 1980 586 592
16. GM Jensen CR Skenes TH Bunch CA Weissman N Amirghahari A Satorius K Moynihan CGS Eley Determination of the relative toxicity of amphotericin B formulations: a red blood cell potassium release assay Drug Deliv 6 1999 81 88
17. RT Proffitt A Satorius S-M Chiang L Sullivan JP Adler-Moore Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents J Antimicrob Chemother 28 suppl B 1991 49 61
18. PJ Smith JA Olson D Constable J Schwartz RT Proffitt JP Adler-Moore Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B J Antimicrob Chemother 59 2007 941 951
19. LH Wang RM Fielding PC Smith LS Guo Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats Pharm Res 12 1995 275 283
20. RM Fielding AW Singer LH Wang S Babbar LS Guo Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs Antimicrob Agents Chemother 36 1992 299 307
21. Z Zhang RM Diener JM Lipman Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats Int J Toxicol 25 2006 285 294
22. GW Boswell I Bekersky D Buell R Hiles TJ Walsh Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats Antimicrob Agents Chemother 42 1998 263 268
23. I Bekersky GW Boswell R Hiles RM Fielding D Buell TJ Walsh Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs Pharm Res 16 1999 1694 1701
24. JR Wingard MH White E Anaissie J Raffalli J Goodman A Arrieta A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia Clin Infect Dis 31 2000 1155 1163
25. MH White RA Bowden ES Sandler Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia Clin Infect Dis 27 1998 296 302
26. CE Swenson WR Perkins P Roberts In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother 42 1998 767 771
27. R Bhamra A Sa'ad LE Bolcsak AS Janoff CE Swenson Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats Antimicrob Agents Chemother 41 1997 886 892
28. J Adler-Moore AmBisome targeting to fungal infections Bone Marrow Transplant 14 suppl 5 1994 S3 S7
29. JP Adler-Moore RT Proffitt AmBisome®: long circulating formulation of amphotericin B MC Woodle G Storm Long circulating liposomes: old drugs, new therapeutics 1998 Springer-Verlag 185 206
30. P Francis JW Lee A Hoffman Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection J Infect Dis 169 1994 356 368
31. MC Allende JW Lee P Francis Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis Antimicrob Agents Chemother 38 1994 518 522
32. JA Olson JP Adler-Moore J Schwartz GM Jensen RT Proffitt Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model Antimicrob Agents Chemother 50 2006 2122 2131
33. RE Lewis G Liao J Hou G Chamilos RA Prince DP Kontoyiannis Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis Antimicrob Agents Chemother 51 2007 1253 1258
34. KV Clemons DA Stevens Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis J Antimicrob Chemother 32 1993 172 465
35. KV Clemons DA Stevens Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis Antimicrob Agents Chemother 35 1991 2144 2146
36. KV Clemons DA Stevens Comparison of a liposomal amphotericin B formulation (AmBisome) and deoxycholate amphotericin B (Fungizone) for the treatment of murine paracoccidioidomycosis J Med Vet Mycol 31 1993 387 394
37. BL Jones LA McLintock Impact of diagnostic markers on early antifungal therapy Curr Opin Infect Dis 16 2003 521 526
38. AH Groll N Giri V Petraitis Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system J Infect Dis 182 2000 274 282
39. KV Clemons RA Sobel PL Williams D Pappagianis DA Stevens Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits Antimicrob Agents Chemother 46 2002 2420 2426
40. J Capilla KV Clemons RA Sobel DA Stevens Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis J Antimicrob Chemother 60 2007 673 676
41. MM Albert L Stahl-Carroll MF Luther JR Graybill Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis J Mycol Med 5 1995 1 6
42. AS Ibrahim V Avanessian B Spellberg JE Edwards Jr Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae Antimicrob Agents Chemother 47 2003 3343 3344
43. AS Ibrahim T Gebremariam MI Husseiny Comparison of lipid amphotericin B preparations in treating murine zygomycosis Antimicrob Agents Chemother 2008 52 [Epub ahead of print].
44. KV Clemons DA Stevens Comparative efficacies of four amphotericin B formulations—Fungizone, amphotec (Amphocil), AmBisome, and Abelcet—against systemic murine aspergillosis Antimicrob Agents Chemother 48 2004 1047 1050
45. B Spellberg J Schwartz Y Fu Comparison of antifungal treatments for murine fusariosis J Antimicrob Chemother 58 2006 973 979
46. JP Adler-Moore S-M Chiang A Satorius Treatment of murine candidiasis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome) J Antimicrob Chemother 28 suppl B 1991 63 71
47. EWM van Etten C van den Heuvel-de Groot IA Bakker-Woudenberg Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice J Antimicrob Chemother 32 1993 723 739
48. JR Perfect KA Wright Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis J Antimicrob Chemother 33 1994 73 81
49. JM Clark RR Whitney SJ Olsen Amphotericin B lipid complex therapy of experimental fungal infections in mice Antimicrob Agents Chemother 35 1991 615 621
50. M Ortoneda J Capilla FJ Pastor I Pujol J Guarro Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis Antimicrob Agents Chemother 46 2002 2273 2275
51. ACAP Leenders S de Marie MT ten Kate IA Bakker-Woudenberg HA Verbrugh Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis J Antimicrob Chemother 38 1996 215 225
52. JR Graybill R Bocanegra Liposomal amphotericin B therapy of murine histoplasmosis Antimicrob Agents Chemother 39 1995 1885 1887
53. JP Gangneux A Sulahian YJ Garin R Farinotti F Derouin Therapy of visceral leishmaniasis due to Leishmania infantum : experimental assessment of efficacy of AmBisome Antimicrob Agents Chemother 40 1996 1214 1218
54. AB Mullen AJ Baillie KC Carter Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B Antimicrob Agents Chemother 42 1998 2722 2725
55. V Yardley SL Croft A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis Int J Antimicrob Agents 13 2000 243 248
56. D Andes N Safdar K Marchillo R Conklin Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models Antimicrob Agents Chemother 50 2006 674 684
57. K Takemoto Y Yamamoto Y Ueda Y Sumita K Yoshida Y Niki Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis J Antimicrob Chemother 53 2004 311 317
58. TJ Walsh JL Goodman P Pappas Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study Antimicrob Agents Chemother 45 2001 3487 3496
59. O Ringdén E Andstrom M Remberger B-M Svahn J Tollemar Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin Bone Marrow Transplant 14 suppl 5 1994 10 14
60. JP Adler-Moore JA Olson RT Proffitt Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis J Antimicrob Chemother 54 2004 1096 1102
61. C Cordonnier M Mohty C Faucher Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study Int J Antimicrob Agents 31 2008 135 141
62. AH Groll CA Lyman V Petraitis Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations Antimicrob Agents Chemother 50 2006 3418 3423
63. EW van Etten M Otte-Lambillion W van Vianen MT ten Kate AJ Bakker-Woudenberg Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans J Antimicrob Chemother 35 1995 509 519
64. J Adler-Moore RT Proffitt AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience J Antimicrob Chemother 49 suppl A 2002 21 30
65. CE Cicogna MH White EM Bernard Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis Antimicrob Agents Chemother 41 1997 259 261
66. SD Allen KN Sorensen MJ Nejdl C Durrant RT Proffitt Prophylactic efficacy of aerolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis J Antimicrob Chemother 34 1994 1001 1013
67. BE Gilbert RT Proffitt Aerosolized AmBisome treatment of pulmonary Cryptococcus neoformans infection in mice J Aerosol Med 9 1996 263 276
68. EJ Ruijgrok AG Vulto EW Van Etten Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats J Antimicrob Chemother 48 2001 89 95
69. EJ Ruijgrok AG Vulto EW Van Etten Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats J Pharm Pharmacol 52 2000 619 627
70. G Rieg B Spellberg J Schwartz Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis Antimicrob Agents Chemother 50 2006 2895 2896
71. A BitMansour JM Brown Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation J Infect Dis 186 2002 134 137
72. A Garcia JP Adler-Moore RT Proffitt Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis Antimicrob Agents Chemother 44 2000 2327 2332
73. D Denning Echinocandin antifungal drugs Lancet 362 2003 1142 1151
74. G Aperis E Mylonakis Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations Expert Opin Investig Drugs 15 2006 579 602
75. C Fohrer L Fornecker Y Nivoix C Cornila C Marinescu R Herbrecht Antifungal combination treatment: a future perspective Int J Antimicrob Agents 27 suppl 1 2006 25 30
76. AM Sugar Antifungal combination therapy: where we stand Drug Resist Updat 1 1998 89 92
77. WJ Steinbach DA Stevens DW Denning Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001 Clin Infect Dis 37 suppl 3 2003 S188 S224
78. F Barchiesi E Spreghini S Tomassetti D Giannini G Scalise Caspofungin in combination with amphotericin B against Candida parapsilosis Antimicrob Agents Chemother 51 2007 941 945
79. F Barchiesi E Spreghini S Tomassetti D Arzeni D Giannini G Scalise Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata Antimicrob Agents Chemother 49 2005 1992 4989
80. M Mariné C Serena FJ Pastor J Guarro Combined antifungal therapy in a murine infection by Candida glabrata J Antimicrob Chemother 58 2006 1295 1298
81. CG Dennis WR Greco Y Brun Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox–/– mouse model of chronic granulomatous disease Antimicrob Agents Chemother 50 2006 422 427
82. E Sionov S Mendlovic E Segal Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis J Infect 53 2006 131 139
83. GM Gonzàlez G Gonzàlez LK Najvar JR Graybill Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model J Antimicrob Chemother 60 2007 1341 1346
84. C Serena FJ Pastor F Gilgado E Mayayo J Guarro Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis Antimicrob Agents Chemother 49 2005 497 502
85. KV Clemons DA Stevens Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis Med Mycol 44 2006 69 73
86. PH Chandrasekar JL Cutright EK Manavathu Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis Clin Microbiol Infect 10 2004 925 928
87. B Spellberg Y Fu JE Edwards Jr AS Ibrahim Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice Antimicrob Agents Chemother 49 2005 830 832
88. J Imai G Singh B Fernandez KV Clemons DA Stevens Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model J Antimicrob Chemother 56 2005 166 171
89. KV Clemons M Espiritu R Parmar DA Stevens Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis Antimicrob Agents Chemother 49 2005 4867 4875
90. WR Kirkpatrick BJ Coco TF Patterson Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis Antimicrob Agents Chemother 50 2006 1567 1569
91. J Meletiadis V Petraitis R Petraitiene Triazole–polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation J Infect Dis 194 2006 1008 1018
92. JR Graybill R Bocanegra GM Gonzalez LK Najvar Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin J Antimicrob Chemother 52 2003 656 662
93. JA Olson JP Adler-Moore PJ Smith RT Proffitt Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin Antimicrob Agents Chemother 49 2005 1902 4895
94. AS Ibrahim T Gebremariam Y Fu JE Edwards Jr B Spellberg Combination echinocandin–polyene treatment of murine mucormycosis Antimicrob Agents Chemother 2008 52 [Epub ahead of print].
95. R Bocanegra LK Najvar S Hernandez DI McCarthy JR Graybill Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis Antimicrob Agents Chemother 49 2005 5139 5141